■68Ga/177Lu-FAP-2286是一种新开发的肿瘤显像剂,显示出可视化和治疗肿瘤基质的潜力。这项研究的目的是评估68Ga-FAP-2286PET/CT和18F-FDGPET/CT在诊断晚期肺癌中的有效性。
■在这项前瞻性研究中,我们分析了2022年9月至2023年6月期间接受68Ga-FAP-2286和18F-FDGPET/CT检查的肺癌患者.病变摄取转化为SUVmax。使用配对T检验比较SUVmax,并记录两种方法检测到的阳性病灶数。
■总共,评估了31名参与者(中位年龄:56岁)。原发性病变中68Ga-FAP-2286的摄取明显高于18F-FDG(9.90±5.61vs.分别为6.09±2.84,P<0.001),淋巴结(7.95±2.75vs.分别为5.55±1.59,P=0.01),和骨转移(7.74±3.72vs.分别为5.66±3.55,P=0.04)。此外,68Ga-FAP-2286PET/CT对淋巴结的检测灵敏度优于18F-FDGPET/CT[100%(137/137)与78.8%(108/137),分别],以及骨转移[100%(384/384)与68.5%(263/384),分别]。然而,两种方法对原发肿瘤的检测灵敏度相当[100%(13/13)].
■与18F-FDGPET/CT相比,68Ga-FAP-2286PET/CT显示出更好的肺癌病灶检测能力,特别是在淋巴结和骨转移中,为177Lu-FAP-2286治疗的疗效提供令人信服的影像学证据。
UNASSIGNED: The 68Ga/177Lu-FAP-2286 is a newly developed tumor imaging agent that shows potential for visualizing and treating tumor stroma. The objective of this research was to evaluate the effectiveness of 68Ga-FAP-2286 PET/CT and 18F-FDG PET/CT in diagnosing advanced lung cancer.
UNASSIGNED: In this prospective study, patients with lung cancer who underwent 68Ga-FAP-2286 and 18F-FDG PET/CT examinations between September 2022 and June 2023 were analyzed. Lesion uptake was converted to SUVmax. A paired T-test was used to compare the SUVmax, and the number of positive lesions detected by the two methods was recorded.
UNASSIGNED: In total, 31 participants (median age: 56 years) were assessed. The uptake of 68Ga-FAP-2286 was significantly higher than that of 18F-FDG in primary lesions (9.90 ± 5.61 vs. 6.09 ± 2.84, respectively, P < 0.001), lymph nodes (7.95 ± 2.75 vs. 5.55 ± 1.59, respectively, P=0.01), and bone metastases (7.74 ± 3.72 vs. 5.66 ± 3.55, respectively, P=0.04). Furthermore, the detection sensitivity of lymph nodes using 68Ga-FAP-2286 PET/CT was superior to that with 18F-FDG PET/CT [100% (137/137) vs. 78.8% (108/137), respectively], as well as for bone metastases [100% (384/384) vs. 68.5% (263/384), respectively]. However, the detection sensitivity for primary tumors using both modalities was comparable [100% (13/13) for both].
UNASSIGNED: Compared to 18F-FDG PET/CT, 68Ga-FAP-2286 PET/CT demonstrated better lesion detection capabilities for lung cancer, particularly in lymph nodes and bone metastases, providing compelling imaging evidence for the efficacy of 177Lu-FAP-2286 treatment.